Selective indications for the use of praziquantel in the treatment of brain cysticercosis.
Open Access
- 1 April 1987
- journal article
- research article
- Published by BMJ in Journal of Neurology, Neurosurgery & Psychiatry
- Vol. 50 (4) , 383-388
- https://doi.org/10.1136/jnnp.50.4.383
Abstract
The selective use of praziquantel for the treatment of brain cysticercosis in human beings is described, based upon the results of clinical tests conducted during a 2 year period. Forty patients with clinical diagnosis of cysticercosis, confirmed and documented by CT, were treated. They are divided into four groups, representative of the various forms of the disease. The results assessed by clinical evaluation and sequential CT, give a ten point criterion of the indications for praziquantel.This publication has 8 references indexed in Scilit:
- [Treatment of cysticercosis using praziquantel. Preliminary report of 10 cases].1983
- [Pharmacokinetic, pharmacologic and toxicologic properties of praziquantel].1982
- [Changes in cerebrospinal fluid induced by praziquantel].1982
- [Praziquantel worldwide].1982
- Treatment of Cysticercosis with Praziquantel in ColombiaThe American Journal of Tropical Medicine and Hygiene, 1982
- Administration of praziquantel in neurocysticercosis.1982
- Toxicological profile of praziquantel, a new drug against cestode and schistosome infections, as compared to some other schistosomicides.1981
- Clinical pharmacology in normal volunteers of praziquantel, a new drug against schistosomes and cestodesEuropean Journal of Clinical Pharmacology, 1978